| ［1］ |
Malumbres M，Harlow E，Hunt T，et al. Cyclin-dependent kinases：a family portrait ［J］. Nat Cell Biol，2009，11（11）：1275-1276.
|
| ［2］ |
Parise C，Caggiano V. Breast cancer cortality among Asian-American women in California：variation according to ethnicity and tumor subtype ［J］. J Breast Cancer，2016，19（2）：112-121.
|
| ［3］ |
Binghe X，Qingyuan Z，Pin Z，et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER-2-negative advanced breast cancer：a randomized，phase 3 trial ［J］. Nat Med，2021，27（11）：1904-1909.
|
| ［4］ |
Hortobagyi GN，Stemmer SM，Burris HA，et al. Updated results from MONALEESA-2 a phase Ⅲ trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive，HER-2-negative advanced breast cancer ［J］. Ann Oncol，2018，29（7）：1541-1547.
|
| ［5］ |
Finn RS，Crown JP，Lang I，et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive，HER-2-negative，advanced breast cancer（PALOMA-1/TRIO-18）：a randomised phase 2 study ［J］. Lancet Oncol，2015，16（1）：25-35.
|
| ［6］ |
Masuda N，Inoue K，Nakamura R，et al. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive，human epidermal growth factor receptor 2-negative advanced breast cancer：PALOMA-3 subgroup analysis of Japanese patients ［J］. Int J Clin Oncol，2019，24（3）：262-273.
|
| ［7］ |
Hortobagyi GN，Stemmer SM，Burris HA，et al. Ribociclib as first-line therapy for HR-positive，advanced breast cancer ［J］. New Engl J Med，2016，375（18）：1738-1748.
|
| ［8］ |
Johnston SRD，Harbeck N，Hegg R，et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+，HER-2-，node-positive，high-risk，early breast cancer（monarchE） ［J］. J Clin Oncol，2020，38（34）：3987-3998.
|
| ［9］ |
Spring LM，Wander SA，Andre F，et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer：past，present，and future ［J］. Lancet，2020，395（10226）：817-827.
|
| ［10］ |
黄聪聪，彭靖，肖勋立，等. CDK4/6抑制剂联合内分泌药物治疗HR阳性/HER2阴性乳腺癌疗效与安全性的Meta分析 ［J］. 中国药房，2023，34（22）：2787-2792.
|
| ［11］ |
Frisoli ML，Essien K，Harris JE. Vitiligo：mechanisms of pathogenesis and treatment ［J］. Annu Rev Immunol，2020，38：621-648.
|
| ［12］ |
Chen JR，Li SL，Li CY. Mechanisms of melanocyte death in vitiligo ［J］. Med Res Rev，2021，41（2）：1138-1166.
|
| ［13］ |
张艳坤，李曼，王芳，等. 白癜风同形反应研究进展 ［J］. 临床皮肤科杂志，2020，49（6）：377-380.
|
| ［14］ |
Naranjo CA，Shear NH，Lanctot KL. Advances in the diagnosis of adverse drug reactions ［J］. J Clin Pharmacol，1992，32（10）：897-904.
|
| ［15］ |
Sollena P，Nikolaou V，Soupos N，et al. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors ［J］. Breast Cancer Res Treat，2021，185（1）：247-253.
|
| ［16］ |
李曼，王芳，王利娟，等. 精神神经因素在白癜风发生、发展和预防中的作用 ［J］. 中国皮肤性病学杂志，2019，33（3）：351-354.
|
| ［17］ |
高雅楠，南璐，贾红燕. CDK4/6抑制剂在乳腺癌免疫微环境中的研究进展 ［J］. 肿瘤预防与治疗，2024，37（6）：519-524.
|
| ［18］ |
Sharaf B，Almasri R，Abdel-Razeq N，et al. Vitiligo-like lesions in a patient with metastatic breast cancer treated with cyclin-dependent kinase（CDK） 4/6 inhibitor：a case report and literature review ［J］. Clin Cosmet Inv Derm，2022，15：5-10.
|
| ［19］ |
Goel S，Decristo MJ，Watt AC，et al. CDK4/6 inhibition triggers anti-tumour immunity ［J］. Nature，2017，548（7668）：471-475.
|
| ［20］ |
Larsabal M，Marti A，Jacquemin C，et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo ［J］. J Am Acad Dermatol，2017，76（5）：863-870.
|
| ［21］ |
Teulings HE，Limpens J，Jansen SN，et al. Vitiligo-like depigmentation in patients with stage Ⅲ-Ⅳ melanoma receiving immunotherapy and its association with survival： a systematic review and meta-analysis ［J］. J Clin Oncol，2015，33（7）：773-781.
|
| ［22］ |
Pasqualoni M，Orlandi A，Palazzo A，et al. Case report：vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer：two cases of premature interruption of therapy and exceptional response ［J］. Front Oncol，2023，13：1067264.
|